1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Zolpidem (tartrate) |
| brand | String | Ambien (IR), Ambien CR (biphasic-release), Edluar (sublingual), Intermezzo (low-dose sublingual for middle-of-night awakening), Zolpimist (oral spray) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Non-benzodiazepine hypnotics|Non-benzodiazepine hypnotic]] • [[:Category:Sleep aids|Sleep aid]] • [[:Category:Schedule IV controlled substances|Schedule IV controlled substance]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' |
| starting_dose | String | '''5 mg PO at bedtime for women, 5-10 mg for men''' (per FDA's 2013 sex-specific dose reduction for women due to slower clearance). Ambien CR 6.25 mg women / 6.25-12.5 mg men. Intermezzo SL 1.75 mg women / 3.5 mg men |
| preparations | String | IR tablets 5, 10 mg; CR tablets 6.25, 12.5 mg; SL tablets 1.75, 3.5, 5, 10 mg; oral spray |
| fda_max | String | 10 mg/day (IR); 12.5 mg/day (CR) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • sublingual • oromucosal spray |
| onset | String | 15-30 minutes |
| duration | String | 6-8 hours (IR); 8 hours (CR via biphasic release) |
| halflife | String | ~2.5 hours'"`UNIQ--ref-0000001A-QINU`"' |
| bioavailability | String | ~70% (oral)'"`UNIQ--ref-0000001B-QINU`"' |
| pregnancy | String | Limited human data; case reports of neonatal sedation with late-pregnancy exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the FDA '''Boxed Warning''' for '''complex sleep behaviors''' (sleep-driving, sleep-walking, sleep-eating, other parasomnias) added in 2019'"`UNIQ--ref-0000001C-QINU`"' |
